Comprehensive Analysis of the Expression, Prognosis, and Biological Significance of PLOD Family in Bladder Cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Anonymous, Erratum: global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;70(4):313. doi:10.3322/caac.21609
   Web of Science ®Google Scholar
• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Breyer J, Wirtz RM, Otto W, et al. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Arch. 2017;470(3):267–274. doi:10.1007/s00428-017-2064-8
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: prostate and Bladder Tumours. Eur Urol. 2016;70:106–119. doi:10.1016/j.eururo.2016.02.028
   PubMed Web of Science ®Google Scholar
• Prasad SM, Decastro GJ, Steinberg GD. Medscape, Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat Rev Urol. 2011;8(11):631–642. doi:10.1038/nrurol.2011.144
   PubMed Web of Science ®Google Scholar
• Cumberbatch MGK, Noon AP. Epidemiology, aetiology and screening of bladder cancer. Transl Androl Urol. 2019;8:5–11. doi:10.21037/tau.2018.09.11
   PubMed Web of Science ®Google Scholar
• Reardon ZD, Patel SG, Zaid HB, et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2015;67(1):165–170. doi:10.1016/j.eururo.2014.01.009
   PubMed Web of Science ®Google Scholar
• Afferi L, Lonati C, Montorsi F, et al. Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer. Eur Urol Oncol. 2022;5(6):722–725. doi:10.1016/j.euo.2022.04.001
   PubMed Web of Science ®Google Scholar
• Claps F, van de Kamp MW, Mayr R, et al. Risk factors associated with positive surgical margins’ location at radical cystectomy and their impact on bladder cancer survival. World J Urol. 2021;39(12):4363–4371. doi:10.1007/s00345-021-03776-5
   PubMed Web of Science ®Google Scholar
• Mathieu R, Lucca I, Roupret M, Briganti A, Shariat SF. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol. 2016;13(8):471–479. doi:10.1038/nrurol.2016.126
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised Phase 3 trial. Lancet Oncol. 2015;16(1):76–86. doi:10.1016/S1470-2045(14)71160-X
   PubMed Web of Science ®Google Scholar
• da Costa JB, Gibb EA, Nykopp TK, et al. Molecular tumor heterogeneity in muscle invasive bladder cancer: biomarkers, subtypes, and implications for therapy. Urol Oncol. 2022;40(7):287–294. doi:10.1016/j.urolonc.2018.11.015
   PubMed Web of Science ®Google Scholar
• Warrick JI, Sjödahl G, Kaag M, et al. Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants. Eur Urol. 2019;75(1):18–22. doi:10.1016/j.eururo.2018.09.003
   PubMed Web of Science ®Google Scholar
• Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338–345. doi:10.1038/nature12625
   PubMed Web of Science ®Google Scholar
• Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer. 2017;16(1):41. doi:10.1186/s12943-017-0600-4
   PubMed Web of Science ®Google Scholar
• Meng Q, Lei T, Zhang M, et al. Identification of proteins differentially expressed in Adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines by proteome analysis. J Cancer Res Clin Oncol. 2013;139(3):509–519. doi:10.1007/s00432-012-1350-8
   PubMed Web of Science ®Google Scholar
• Mertens LS, Claps F, Mayr R, et al. Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. Urol Oncol. 2022;40(3):110 e111–110 e119. doi:10.1016/j.urolonc.2021.10.010
   Web of Science ®Google Scholar
• Mori K, Janisch F, Mostafaei H, et al. Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: a systematic review and meta-analysis. Urol Oncol. 2020;38(5):315–333. doi:10.1016/j.urolonc.2020.01.015
   PubMed Web of Science ®Google Scholar
• Claps F, Rai S, Mir MC, et al. Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy. Urol Oncol. 2021;39(12):835 e839–835 e817. doi:10.1016/j.urolonc.2021.04.026
   Web of Science ®Google Scholar
• Schuettfort VM, D`Andrea D, Quhal F, et al. Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Urol Oncol. 2021;39(4):235 e235–235 e214. doi:10.1016/j.urolonc.2020.11.005
   Web of Science ®Google Scholar
• Laukhtina E, Pradere B, Lemberger U, et al. Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder. Curr Opin Urol. 2022;32(5):561–566. doi:10.1097/MOU.0000000000001013
   PubMed Web of Science ®Google Scholar
• Claps F, Mir MC, Zargar H. Molecular markers of systemic therapy response in urothelial carcinoma. Asian J Urol. 2021;8(4):376–390. doi:10.1016/j.ajur.2021.05.001
   PubMed Web of Science ®Google Scholar
• Mir MC, Campi R, Loriot Y, et al. Adjuvant systemic therapy for high-risk muscle-invasive bladder cancer after radical cystectomy: current options and future opportunities. Eur Urol Oncol. 2022;5(6):726–731. doi:10.1016/j.euo.2021.04.004
   PubMed Web of Science ®Google Scholar
• de Kruijff IE, Beije N, Martens JWM, et al. Liquid biopsies to select patients for perioperative chemotherapy in muscle-invasive bladder cancer: a systematic review. Eur Urol Oncol. 2021;4(2):204–214. doi:10.1016/j.euo.2020.01.003
   PubMed Web of Science ®Google Scholar
• Qi Y, Xu R. Roles of PLODs in collagen synthesis and cancer progression. Front Cell Dev Biol. 2018;6:66. doi:10.3389/fcell.2018.00066
   PubMed Web of Science ®Google Scholar
• Valtavaara M, Szpirer C, Szpirer J, Myllyla R. Primary structure, tissue distribution, and chromosomal localization of a novel isoform of lysyl hydroxylase (lysyl hydroxylase 3). J Biol Chem. 1998;273(21):12881–12886. doi:10.1074/jbc.273.21.12881
   PubMed Web of Science ®Google Scholar
• Kurozumi A, Kato M, Goto Y, et al. Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma. Int J Oncol. 2016;48(5):1837–1846. doi:10.3892/ijo.2016.3440
   PubMed Web of Science ®Google Scholar
• Provenzano PP, Inman DR, Eliceiri KW, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008;6(1):11. doi:10.1186/1741-7015-6-11
   PubMedGoogle Scholar
• Zhang J, Tian Y, Mo S, Fu X. Overexpressing PLOD family genes predict poor prognosis in pancreatic cancer. Int J Gen Med. 2022;15:3077–3096. doi:10.2147/IJGM.S341332
   PubMed Web of Science ®Google Scholar
• Qi Q, Huang W, Zhang H, et al. Bioinformatic analysis of PLOD family member expression and prognostic value in non-small cell lung cancer. Transl Cancer Res. 2021;10(6):2707–2724. doi:10.21037/tcr-21-73
   PubMed Web of Science ®Google Scholar
• Li SS, Lian YF, Huang YL, Huang YH, Xiao J. Overexpressing PLOD family genes predict poor prognosis in gastric cancer. J Cancer. 2020;11:121–131. doi:10.7150/jca.35763
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. doi:10.1126/science.1260419
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon J-C, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174. doi:10.1186/s13059-016-1028-7
   PubMed Web of Science ®Google Scholar
• Liu CJ, Hu -F-F, Xia M-X, et al. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018;34(21):3771–3772. doi:10.1093/bioinformatics/bty411
   PubMed Web of Science ®Google Scholar
• Liu J, Lichtenberg T, Hoadley KA, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400–416 e411. doi:10.1016/j.cell.2018.02.052
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Li L, Wang W, Li X, Gao T. Association of ECRG4 with PLK1, CDK4, PLOD1 and PLOD2 in esophageal squamous cell carcinoma. Am J Transl Res. 2017;9:3741–3748.
   PubMed Web of Science ®Google Scholar
• Gjaltema RAF, de Rond S, Rots MG, Bank RA. Procollagen lysyl hydroxylase 2 expression is regulated by an alternative downstream transforming growth factor beta-1 activation mechanism. J Biol Chem. 2015;290:28465–28476. doi:10.1074/jbc.M114.634311
   PubMed Web of Science ®Google Scholar
• Jover E, Silvente A, Marin F, et al. Inhibition of enzymes involved in collagen cross-linking reduces vascular smooth muscle cell calcification. FASEB J. 2018;32(8):4459–4469. doi:10.1096/fj.201700653R
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang S, Chen F. High expression of PLOD1 drives tumorigenesis and affects clinical outcome in gastrointestinal carcinoma. Genet Test Mol Biomarkers. 2018;22:366–373. doi:10.1089/gtmb.2018.0009
   PubMed Web of Science ®Google Scholar
• Yuan B, Xu Y, Zheng S. PLOD1 acts as a tumor promoter in glioma via activation of the HSF1 signaling pathway. Mol Cell Biochem. 2022;477:549–557. doi:10.1007/s11010-021-04289-w
   PubMed Web of Science ®Google Scholar
• Li B, Yang H, Shen B, Huang J, Qin Z. Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 increases cellular proliferation and colony formation capacity in lung cancer via activation of E2F transcription factor 1. Oncol Lett. 2021;22:851. doi:10.3892/ol.2021.13112
   PubMed Web of Science ®Google Scholar
• Jiang H, Guo W, Yuan S, Song L. PLOD1 is a prognostic biomarker and mediator of proliferation and invasion in osteosarcoma. Biomed Res Int. 2020;2020:3418398. doi:10.1155/2020/3418398
   PubMed Web of Science ®Google Scholar
• Yamada Y, Kato M, Arai T, et al. Aberrantly expressed PLOD 1 promotes cancer aggressiveness in bladder cancer: a potential prognostic marker and therapeutic target. Mol Oncol. 2019;13(9):1898–1912. doi:10.1002/1878-0261.12532
   PubMed Web of Science ®Google Scholar
• Galkina SI, Fedorova NV, Ksenofontov AL, et al. Neutrophils as a source of branched-chain, aromatic and positively charged free amino acids. Cell Adh Migr. 2019;13(1):98–105. doi:10.1080/19336918.2018.1540903
   PubMed Web of Science ®Google Scholar
• Risteli M, Ruotsalainen H, Salo AM, et al. Reduction of lysyl hydroxylase 3 causes deleterious changes in the deposition and organization of extracellular matrix. J Biol Chem. 2009;284(41):28204–28211. doi:10.1074/jbc.M109.038190
   PubMed Web of Science ®Google Scholar
• van der Slot AJ, Zuurmond A-M, Bardoel AFJ, et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem. 2003;278(42):40967–40972. doi:10.1074/jbc.M307380200
   PubMed Web of Science ®Google Scholar
• Hu HL, Wang C-F, Wei X-H, et al. Correlation between procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 and breast cancer. Int J Clin Exp Pathol. 2019;12(3):1015–1021.
   PubMed Web of Science ®Google Scholar
• Song Y, Zheng S, Wang J, et al. Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/Akt signaling in glioma. Oncotarget. 2017;8(26):41947–41962. doi:10.18632/oncotarget.16710
   PubMedGoogle Scholar
• Li G, Wang X, Liu G. PLOD2 Is a Potent Prognostic Marker and Associates with Immune Infiltration in Cervical Cancer. Biomed Res Int. 2021;2021:5512340. doi:10.1155/2021/5512340
   PubMed Web of Science ®Google Scholar
• Eisinger-Mathason TS, Zhang M, Qiu Q, et al. Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov. 2013;3(10):1190–1205. doi:10.1158/2159-8290.CD-13-0118
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Seki N, Matsushita R, et al. Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer. Br J Cancer. 2016;115(3):354–363. doi:10.1038/bjc.2016.179
   PubMed Web of Science ®Google Scholar
• Yang B, Zhao Y, Wang L, et al. Identification of PLOD Family Genes as Novel Prognostic Biomarkers for Hepatocellular Carcinoma. Front Oncol. 2020;10:1695. doi:10.3389/fonc.2020.01695
   PubMedGoogle Scholar
• Wang Z, Fan G, Zhu H, et al. PLOD2 high expression associates with immune infiltration and facilitates cancer progression in osteosarcoma. Front Oncol. 2022;12:980390. doi:10.3389/fonc.2022.980390
   PubMed Web of Science ®Google Scholar
• Xie D, Li J, Wei S, et al. Knockdown of PLOD3 suppresses the malignant progression of renal cell carcinoma via reducing TWIST1 expression. Mol Cell Probes. 2020;53:101608. doi:10.1016/j.mcp.2020.101608
   PubMed Web of Science ®Google Scholar
• Baek JH, Yun HS, Kwon GT, et al. PLOD3 suppression exerts an anti-tumor effect on human lung cancer cells by modulating the PKC-delta signaling pathway. Cell Death Dis. 2019;10(3):156. doi:10.1038/s41419-019-1405-8
   PubMedGoogle Scholar
• Wang B. PLOD3 is upregulated in gastric cancer and correlated with clinicopathologic characteristics. Clin Lab. 2019;65. doi:10.7754/Clin.Lab.2018.180541
   Web of Science ®Google Scholar
• Tsai CK, Huang L-C, Tsai W-C, et al. Overexpression of PLOD3 promotes tumor progression and poor prognosis in gliomas. Oncotarget. 2018;9:15705–15720. doi:10.18632/oncotarget.24594
   PubMedGoogle Scholar